MA39778A - Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants - Google Patents

Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants

Info

Publication number
MA39778A
MA39778A MA039778A MA39778A MA39778A MA 39778 A MA39778 A MA 39778A MA 039778 A MA039778 A MA 039778A MA 39778 A MA39778 A MA 39778A MA 39778 A MA39778 A MA 39778A
Authority
MA
Morocco
Prior art keywords
gated sodium
sodium channel
channel modulators
sulfonamide compounds
voltage gated
Prior art date
Application number
MA039778A
Other languages
English (en)
Inventor
Moloy Banerjee
Amit Kumar Das
Rajender Kumar Kamboj
Talha Hussain Khan
Rajeshkumar Maganlal Loriya
Venkata P Palle
Vidya Ramdas
Deepak Sahebrao Walke
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MA39778A publication Critical patent/MA39778A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne le composé de formule (i) dans laquelle les substituants sont tels que décrits dans la description, et leur utilisation dans un médicament destiné au traitement de maladies, de troubles associés à l'inhibition des canaux sodiques potentiel-dépendants (vgsc) en particulier na
MA039778A 2014-03-29 2015-03-27 Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants MA39778A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1170MU2014 2014-03-29
IN566MU2015 2015-02-20

Publications (1)

Publication Number Publication Date
MA39778A true MA39778A (fr) 2017-02-08

Family

ID=54239471

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039778A MA39778A (fr) 2014-03-29 2015-03-27 Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants

Country Status (7)

Country Link
US (1) US20170137415A1 (fr)
EP (1) EP3126360A1 (fr)
AU (1) AU2015242219A1 (fr)
CA (1) CA2944115A1 (fr)
MA (1) MA39778A (fr)
TW (1) TW201623264A (fr)
WO (1) WO2015151001A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201722938A (zh) 2015-09-04 2017-07-01 魯賓有限公司 作為電位閘控鈉通道調節子之磺醯胺化合物
TW201726637A (zh) 2015-12-18 2017-08-01 默沙東藥廠 對電位閘控鈉通道具選擇活性之羥基烷基胺－及羥基環烷基胺－取代之二胺－芳基磺胺化合物
ES2897998T3 (es) * 2016-10-27 2022-03-03 Bristol Myers Squibb Co Inhibidores de la acilsulfonamida del NaV1.7
WO2018163077A1 (fr) 2017-03-08 2018-09-13 Lupin Limited Composés indanyle utilisés en tant que modulateurs de canaux sodiques dépendant de la tension
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
CN110621669A (zh) 2017-05-04 2019-12-27 巴斯夫欧洲公司 防除植物病原性真菌的取代5-卤代烷基-5-羟基异噁唑类
WO2020048829A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés de 3,9-diazaspiro[5.5]undécane
WO2020048828A1 (fr) 2018-09-03 2020-03-12 Bayer Pharma Aktiengesellschaft Composés du 5-hétéroaryl-3,9-diazaspiro[5.5]undécane

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001289831A1 (en) 2000-09-06 2002-03-22 Bayer Aktiengesellschaft Medicaments against viral infections
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
WO2007109324A2 (fr) 2006-03-21 2007-09-27 Xenon Pharmaceuticals, Inc. Bloqueurs puissants et sélectifs du canal sodique nav1.7
WO2008046087A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Composés spiro et leurs utilisations en tant qu'agents thérapeutiques
CL2007002950A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Uso de compuestos derivados de espiro-oxindol en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer
WO2008046084A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques et utilisation de ceux-ci comme agents thérapeutiques
US20110294842A9 (en) 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2173743A2 (fr) 2007-07-13 2010-04-14 Icagen, Inc. Inhibiteurs des canaux sodiques
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
WO2010035166A1 (fr) 2008-09-23 2010-04-01 Pfizer Limited Dérivés de benzamide
EP2350091B1 (fr) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Composés spiro-oxindole et leur utilisation comme agents thérapeutiques
US8263606B2 (en) 2008-10-17 2012-09-11 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010053998A1 (fr) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Dérivés d'indole spiro-condensés utilisables en tant qu'inhibiteurs des canaux sodiques
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
WO2010151597A1 (fr) 2009-06-26 2010-12-29 Schering Corporation Procédés d'utilisation de pyrrolo-benzo-1,4-diazines en tant que bloqueurs de canaux sodiques
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011026240A1 (fr) 2009-09-04 2011-03-10 Zalicus Pharmaceuticals Ltd. Dérivés d'oxopipérazine pour le traitement de la douleur et de l'épilepsie
WO2011056985A2 (fr) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Composés hétérocycliques substitués
WO2011058766A1 (fr) 2009-11-16 2011-05-19 Raqualia Pharma Inc. Dérivés d'arylcarboxamide comme bloqueurs de ttx-s
TW201139406A (en) 2010-01-14 2011-11-16 Glaxo Group Ltd Voltage-gated sodium channel blockers
WO2011103196A1 (fr) 2010-02-17 2011-08-25 Amgen Inc. Dérivés d'arylcarboxamide en tant qu'inhibiteurs de canal sodique pour le traitement de la douleur
CA2812526A1 (fr) 2010-05-06 2011-11-10 Vertex Pharmaceuticals Incorporated Amides de chromene heterocyclique-piperidine spirocyclique utiles comme modulateurs des canaux ioniques
US9045435B2 (en) 2010-10-05 2015-06-02 Purdue Pharma, L.P. Quinazoline compounds as sodium channel blockers
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US9273040B2 (en) 2011-10-28 2016-03-01 Merck Sharp & Dohme Corp. Benzoxazolinone compounds with selective activity in voltage-gated sodium channels
US9012443B2 (en) * 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2013122897A1 (fr) * 2012-02-13 2013-08-22 Amgen Inc. Inhibiteurs des canaux sodiques de type dihydrobenzoxazine et tétrahydroquinoxaline
US9051311B2 (en) 2012-03-09 2015-06-09 Amgen Inc. Sulfamide sodium channel inhibitors
US9212182B2 (en) 2013-06-12 2015-12-15 Amgen Inc. Bicyclic sulfonamide compounds as sodium channel inhibitors
WO2015010065A1 (fr) 2013-07-19 2015-01-22 Vertex Pharmaceuticals Incorporated Sulfamides utilisés comme modulateurs des canaux sodium

Also Published As

Publication number Publication date
CA2944115A1 (fr) 2015-10-08
AU2015242219A1 (en) 2016-10-06
EP3126360A1 (fr) 2017-02-08
WO2015151001A1 (fr) 2015-10-08
US20170137415A1 (en) 2017-05-18
TW201623264A (zh) 2016-07-01

Similar Documents

Publication Publication Date Title
MA39778A (fr) Composés sulfonamides comme modulateurs des canaux sodiques potentiel-dépendants
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2015017215A (es) Compuestos de sulfonamida biciclicos como inhibidores de los canales de sodio.
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
EP3010506A4 (fr) Utilisation de pridopidine à forte dose pour traiter la maladie de huntington
MX2017006382A (es) Analogos de eter fosfolipidico como portadores de farmacos dirigidos a cancer.
MX364486B (es) Derivados de piridazinona-amidas.
EA201391106A1 (ru) Новые гетероциклические производные
GEP20186903B (en) Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
UY33910A (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del SNC
BR112017010440A2 (pt) administração sublingual de riluzol
PH12017500533A1 (en) 1-alkyl-6-oxo-1, 6-dihydropyridin-3-yl compounds and use as sgrm modulators
EA033250B1 (ru) Пирролидиновые модуляторы gpr40 для лечения расстройств, таких как диабет
PH12017500747A1 (en) Heterocyclic compound
MX2016009589A (es) Enonas piridazolilo y pirimidinilo triciclicas sustituidas con arilo y arilalquilo como moduladores de la inflamacion antioxidantes.
MX2017005044A (es) Activador de canales de kcnq2-5.
BR112017010423A2 (pt) formulação sublingual de riluzol
GT201400242A (es) "nuevos compuestos de pirazol"
IN2014MN01469A (fr)
PH12018500469A1 (en) Sulfonamide compounds as voltage-gated sodium channel modulators
IN2014MN02393A (fr)